Published 07/27/2024 2:28:00 p.m.

EU regulators under fire after rejecting breakthrough Alzheimer’s medicine

Summary by Ground News

The European Union’s drug regulator has come under fire for blocking a breakthrough Alzheimer’s drug that already has market approval in five other countries. European Medicines Agency (EMA) committee recommended on Friday that Leqembi, also known as lecanemab, be denied market authorisation in the EU despite the treatment reducing cognitive decline in Alzheimer’s patients by 27 per cent in a late-stage clinical trial.

0 Articles

All

Left

Center

Right

BBC News

EU regulator rejects Alzheimer's drug lecanemab

It said the benefits of the treatment did not outweigh the risk of serious side effects.

07/26/2024 5:01:49 p.m.·United Kingdom

Read Full Article

The Sun

'Disappointing' blow as Alzheimer's drug lecenemab is rejected by EU

EUROPE has rejected a breakthrough Alzheimer’s drug in a blow to NHS hopes.Lecanemab is one of the first medicines ever proven to destroy toxic amyl

07/26/2024 4:02:07 p.m.·United Kingdom

Read Full Article

The Telegraph

EU regulators under fire after rejecting breakthrough Alzheimer’s medicine

Risk of side effects are overstated claims professor after committee denies drug that already has market approval in five other countries

07/27/2024 9:46:00 a.m.·London, United Kingdom

Read Full Article

The Business Journals

EU regulator rejects Biogen, Eisai’s Alzheimer's drug

The European Union's drug regulator laid out why it decided not to approve an Alzheimer's disease drug made by Eisai Inc. and Cambridge’s Biogen Inc. All eyes now move to Biogen's second-quarter earnings call next week.

07/26/2024 2:34:16 p.m.·United States

Read Full Article

Le Parisien

Alzheimer: The European Medicines Agency blocks a highly anticipated treatment.

The European Medicines Agency ruled on Friday against the marketing of Leqembi, a treatment aimed at reducing cognitive decline in patients suffering from Alzheimer's disease.

07/26/2024 9:52:00 p.m.·Paris, France

Read Full Article

Zeit Online

Alzheimer's drug lecanemab: EU authority rejects recommendation of Alzheimer's drug

The EU Medicines Agency EMA rejects the recommendation of the Alzheimer's drug lecanemab. The positive effect does not outweigh the risk of serious side effects, it was said.

07/26/2024 1:46:16 p.m.·Germany

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year